Secondary cytoreduction in ovarian cancer: who really benefits?
To identify women affected by recurrent ovarian cancer who benefit from secondary cytoreductive surgery (SCS), analyse their clinical and biological features and investigate the role of minimally invasive surgery (MIS) and hyperthermic intraperitoneal-based chemotherapy (HIPEC) in this subset of patients.
This narrative review examines the data available from the updated literature. An electronic literature search was conducted in PubMed Medline databases for articles published from 1990 to 2018.
Retrospective studies and preliminary data from the AGO-Desktop III trial show that cytoreductive surgery is associated with improved post-relapse survival in patients with platinum-sensitive relapse, compared to chemotherapy alone. This benefit is more evident in patients treated with complete or optimal primary debulking surgery at referral centres, who did not receive bevacizumab in first-line chemotherapy, and who present a localized pattern of disease. MIS has been proven to be a favourable approach to achieve a complete secondary debulking, reducing peri- and postoperative comorbidities. The application of HIPEC to SCS is associated with an improvement in oncological outcomes by preliminary results.
While waiting for the final results of the ongoing randomized controlled trials, SCS seems feasible and safe in selected patients with recurrent ovarian cancer. Recently, more attention has been focused on the biological features of ovarian tumours, such as BRCA status. Further studies and molecular research should be conducted to identify individualized and targeted therapies in the treatment of ovarian cancer recurrences.
KeywordsSecondary cytoreductive surgery Recurrent ovarian cancer Personalized treatment Biological features Minimally invasive surgery
MTG: Protocol/project development, Data collection, Manuscript writing and Manuscript editing. MD’I: Protocol/project development, Data collection, Manuscript writing and Manuscript editing. SC: Protocol/project development, Data collection. VG: Protocol/project development and Manuscript editing. AF: Protocol/project development and Manuscript editing. GS: Protocol/project development, Manuscript writing and Manuscript editing. MP: Protocol/project development, Data collection, Manuscript writing and Manuscript editing. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 8.National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Ovarian Cancer. Version 1.2017. Available online at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian
- 18.Luo Y, Lee M, Kim HS et al (2016) Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95:36Google Scholar
- 21.Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 21(2):289–295CrossRefPubMedCentralGoogle Scholar
- 23.Coleman RL, Brady MF, Herzog TJ et al (2015) A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). Presented at: Society of Gynecologic Oncology 2015 annual meeting on women’s cancer; 28–31 March, 2015; Chicago, Abstract 3Google Scholar
- 43.Zivanovic O, Abramian A, Kullmann M (2015) HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 136(3):699–708PubMedPubMedCentralGoogle Scholar
- 46.Fagotti A, Costantini B, Gallotta V et al (2015) Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes. J Minim Invasive Gynecol. 22(3):428–432CrossRefPubMedCentralGoogle Scholar